Previous 10 | Next 10 |
Atara Biotherapeutics (ATRA): Q1 GAAP EPS of -$0.86 beats by $0.08.Revenue of $3.55M beats by $1.95M.Cash, cash equivalents and short-term investments as of March 31, 2021 totaled $435.2 million, as compared to $500.7 million as of December 31, 2020Atara believes that its cash as of March 31,...
Conference Call and Webcast Today at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tu...
Live Conference Call and Webcast at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tum...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Granted, finding stocks that could double by summer is no easy feat! After all, the markets have been rocky lately. And with interest rates rising, the growth plays have been under lots of pressure and there has been a rota...
Calling the company ‘an oncology diamond,’ Evercore ISI has initiated coverage on Viracta Therapeutics ([[VIRX]] +11.5%) with an outperform rating. Its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas underlies the firm’s thesis.The price target ...
Updated interim data provided by AstraZeneca (AZN) yesterday from its late-stage COVID-19 vaccine trial in the U.S., should address the data integrity issue, UBS wrote in a note. AstraZeneca ADRs are trading marginally up in before hours.The Analysts led by Michael Leuchten with a buy ra...
Today, we revisit Atara Biotherapeutics for the first time since August of last year when we recommended it as a solid covered call candidate. The stock has delivered on that promise and the company continues to advance its pipeline. We update our investment thesis on Atara in the...
Atara Biotherapeutics (ATRA) announces a combined long-term overall survival ((OS)) analysis from clinical study of tabelecleucel (tab-cel) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after hematopoietic cell transplantation ((HCT)). Comb...
Over 80 percent overall survival rates at two years among patients with complete response (CR) as well as among patients with partial response (PR) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell p...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announ...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...